Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Treatment using reprogrammed mature adult cells

A technology of reprogramming and cells, which is applied in the direction of extracellular fluid diseases, medical preparations containing active ingredients, and medical raw materials derived from mammals, etc. It can solve the problems of limited number of stem cells, troubles, and difficulties in stem cell differentiation.

Inactive Publication Date: 2012-08-22
TRISTEM TRADING CYPRUS
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, extraction from these sources is cumbersome, sometimes dangerous, and may be challenged by ethical concerns
Furthermore, the number of stem cells available from these sources is limited
Also, stem cells may have difficulty differentiating into the cells needed to treat disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment using reprogrammed mature adult cells
  • Treatment using reprogrammed mature adult cells
  • Treatment using reprogrammed mature adult cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0179] Materials and methods

[0180] This clinical study evaluated the safety of a single dose of autologous reprogrammed cells infused 3 hours after exposure to hematopoietic-inducing culture conditions into four aplastic anemia patients.

[0181] This clinical study was approved by the Ethics Committee of the King Edward Memorial (KEM) Hospital and conducted in collaboration with the Institute of Immunohematology (IIH). Patients were required to meet the criteria outlined in Table 3. As a result, four patients with severe (3 males) and aplastic (1 female) anemia were enrolled into the study. These 4 patients were selected and monitored by IIH / KEM staff. The patient's clinical and treatment history is described in Table 4, while his CD34 + Cell infusion doses are shown in Table 5.

[0182] Table 3: Inclusion Criteria

[0183]

[0184] Patients are transfused with 2 units of irradiated packed red blood cells and 4 units of platelets to maintain their hemoglobin levels...

Embodiment 2

[0221] Materials and methods

[0222] Autologous reprogrammed hematopoietic cells (target cells) were tested in 21 beta thalassemia patients. Nineteen patients had beta thalassemia major, while 2 patients had thalassemia intermedia. One of the β-thalassemia intermedia patients had a thalassemia / Hb E variant (commonly seen in patients of Far Eastern and Indian origin), while the other had thalassemia / sickle cell anemia.

[0223] Apheresis is performed on the patient by processing 2-3 times the total volume of the patient's blood. Autologous reprogrammed cells are produced by reprogramming leukocytes until target cells are obtained as indicated by their distinguishing features as described above. The autologous reprogrammed cells are administered to the patient by intravenous infusion into the jugular vein or a vein in the arm or thigh.

[0224] result

[0225]Following infusion of reprogrammed cells, no toxicity or adverse side effects were observed in beta thalassemia ...

Embodiment 3

[0229] Materials and methods

[0230] Apheresis was performed on two diabetic patients by processing 2-3 times the total amount of patient blood. Autologous reprogrammed mesenchymal stem cells, pluripotent stem cells and islet cells (target cells) were obtained by reprogramming apheresis leukocytes until the target cells developed as indicated by their distinguishing features as described above. The autologous reprogrammed cells are administered to the patient by intravenous infusion into the jugular vein or a vein in the arm or thigh.

[0231] result

[0232] Following infusion of autologous reprogrammed cells, patients synthesized normal levels of insulin, as measured by c-peptide stimulated by fasting and 90-minute food intake. This normal level of c-peptide was maintained until 3 months after infusion of the reprogrammed cells ( Figure 9 ). Furthermore, Hb A1C levels (which are indicative of glycemic control) were normalized after infusion of reprogrammed cells ( ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In certain embodiments, the method comprises obtaining committed cells from the patient, transdifferentiating the committed cells to obtain transdifferentiated target cells, and administering the transdifferentiated target cells to the patient. The retrodifferentiated or transdifferentiated target cells repair or replenish tissue or cells in the patient.

Description

[0001] incorporated by reference [0002] All documents cited or referenced in documents cited herein, as well as any manufacturer's instructions, instructions, product specifications, and product pages for any product mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference , and can be used in the practice of the present invention. field of invention [0003] Methods of treating various diseases, disorders or conditions in a patient using reprogrammed cells, such as retrodifferentiated, transdifferentiated or redifferentiated cells. The method includes obtaining committed cells from a patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In some embodiments, the method comprises obtaining committed cells from the patient, transdifferentiating the committed cells to obtain transdifferentiated target cells, and admini...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/14A61P7/00A61P9/04A61P7/06A61P31/18A61P25/00A61P11/00A61P25/16A61P5/00A61P21/00A61P17/02A61K35/22A61K35/28A61K35/30A61K35/34A61K35/39A61K35/545
CPCA61K35/22A61K35/28A61K35/30A61K35/34A61K35/39A61K35/545A61P1/16A61P11/00A61P13/12A61P15/00A61P15/08A61P17/00A61P17/02A61P17/06A61P17/14A61P21/00A61P21/04A61P25/00A61P25/02A61P25/16A61P25/24A61P27/02A61P31/14A61P31/18A61P37/02A61P5/00A61P7/00A61P7/06A61P9/04A61P3/10A61K2300/00A61K35/14
Inventor I.M.S.S.阿布尔贾达耶尔
Owner TRISTEM TRADING CYPRUS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com